A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study will consider the safety and effectiveness of a study drug, CAN04, in combination
with pembrolizumab, in the treatment of incurable or metastatic non-small-cell lung cancer,
head and neck squamous cell carcinoma, urothelial cancer, or malignant melanoma. The study
aims to establish a recommended dose of CAN04 in combination with the standard dose of
pembrolizumab. Both CAN04 and pembrolizumab will be administered intravenously.